Gene symbol |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
Akt1 |  |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 |  |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 |  |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Btk |  |
NM_013482 |
Bruton agammaglobulinemia tyrosine kinase (Btk), mRNA [NM_013482] |
KLA | 1.10 |
1.24 |
1.01 |
1.33 |
1.07 |
1.27 |
1.01 |
| ATP | .95 |
1.05 |
.86 |
.97 |
.66 |
.72 |
.82 |
| KLA/ATP | 1.14 |
1.35 |
1.12 |
1.52 |
.96 |
.70 |
.82 |
|
Csf2 |  |
NM_009969 |
colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] |
KLA | 1.44 |
1.53 |
1.38 |
1.37 |
1.15 |
1.21 |
1.14 |
| ATP | 1.01 |
1.02 |
1.85 |
9.73 |
2.64 |
1.90 |
1.14 |
| KLA/ATP | 1.49 |
1.84 |
2.14 |
2.80 |
1.67 |
1.36 |
1.35 |
|
EG629860
|  |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
Fcer1a |  |
NM_010184 |
Fc receptor, IgE, high affinity I, alpha polypeptide (Fcer1a), mRNA [NM_010184] |
KLA | 1.14 |
.98 |
1.02 |
1.09 |
1.00 |
1.00 |
.96 |
| ATP | 1.04 |
1.03 |
1.07 |
.97 |
1.04 |
1.01 |
1.06 |
| KLA/ATP | .94 |
.98 |
1.09 |
1.04 |
1.06 |
.94 |
.95 |
|
Fcer1g |  |
J05020 |
gb|Mouse mast cell high affinity IgE receptor (Fc-epsilon-RI) gamma subunit mRNA, complete cds. [J05020] |
KLA | 1.41 |
1.43 |
1.53 |
1.61 |
1.91 |
2.07 |
2.49 |
| ATP | 1.13 |
1.21 |
.88 |
1.25 |
1.06 |
.92 |
1.45 |
| KLA/ATP | 1.64 |
1.64 |
1.25 |
1.84 |
1.45 |
1.39 |
2.32 |
|
Fcer1g |  |
NM_010185 |
Fc receptor, IgE, high affinity I, gamma polypeptide (Fcer1g), mRNA [NM_010185] |
KLA | 1.49 |
1.54 |
1.48 |
1.62 |
2.18 |
2.06 |
2.35 |
| ATP | 1.10 |
1.16 |
.78 |
1.00 |
.90 |
.98 |
1.18 |
| KLA/ATP | 1.48 |
1.67 |
1.26 |
1.71 |
1.33 |
1.40 |
2.13 |
|
Fyn |  |
U70324 |
Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] |
KLA | 1.23 |
1.27 |
1.31 |
1.27 |
1.31 |
.87 |
.48 |
| ATP | .88 |
.71 |
.66 |
.75 |
.90 |
1.28 |
.51 |
| KLA/ATP | 1.12 |
1.01 |
.94 |
.84 |
1.25 |
1.51 |
.53 |
|
Gab2 |  |
NM_010248 |
growth factor receptor bound protein 2-associated protein 2 (Gab2), mRNA [NM_010248] |
KLA | 1.01 |
1.04 |
1.04 |
1.02 |
1.12 |
1.16 |
1.14 |
| ATP | 1.02 |
1.06 |
1.00 |
1.13 |
1.16 |
1.19 |
1.23 |
| KLA/ATP | 1.06 |
1.05 |
1.03 |
1.02 |
1.03 |
1.04 |
1.29 |
|
Grb2 |  |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 |  |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Hras1 |  |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Igh-VJ55 8 |  |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 |  |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 |  |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 |  |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 |  |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Il13 |  |
NM_008355 |
interleukin 13 (Il13), mRNA [NM_008355] |
KLA | 1.08 |
1.05 |
.98 |
1.10 |
1.01 |
1.03 |
1.02 |
| ATP | 1.00 |
.98 |
1.08 |
.98 |
.99 |
1.05 |
.97 |
| KLA/ATP | .96 |
.96 |
1.09 |
1.02 |
1.04 |
1.01 |
.97 |
|
Il3 |  |
NM_010556 |
interleukin 3 (Il3), mRNA [NM_010556] |
KLA | 1.05 |
.94 |
1.01 |
.99 |
1.03 |
1.07 |
.95 |
| ATP | .95 |
1.03 |
1.03 |
.98 |
.98 |
.97 |
.96 |
| KLA/ATP | 1.02 |
1.03 |
1.02 |
.94 |
.97 |
1.02 |
1.04 |
|
Il4 |  |
NM_021283 |
interleukin 4 (Il4), mRNA [NM_021283] |
KLA | .94 |
.95 |
.91 |
.94 |
.91 |
.94 |
1.07 |
| ATP | 1.02 |
1.06 |
1.05 |
1.22 |
1.12 |
1.10 |
1.26 |
| KLA/ATP | .92 |
.96 |
.93 |
1.08 |
.98 |
1.03 |
1.18 |
|
Il5 |  |
NM_010558 |
interleukin 5 (Il5), mRNA [NM_010558] |
KLA | 1.10 |
1.11 |
1.10 |
.98 |
1.01 |
.98 |
.97 |
| ATP | .94 |
1.04 |
1.08 |
.92 |
.97 |
1.02 |
1.03 |
| KLA/ATP | .98 |
.92 |
1.12 |
1.03 |
1.02 |
1.00 |
1.03 |
|
Inpp5d |  |
NM_010566 |
inositol polyphosphate-5-phosphatase D (Inpp5d), transcript variant 1, mRNA [NM_010566] |
KLA | .17 |
.15 |
.13 |
.20 |
.56 |
1.17 |
.81 |
| ATP | 1.09 |
1.05 |
.86 |
.70 |
.37 |
.42 |
1.25 |
| KLA/ATP | .18 |
.15 |
.14 |
.12 |
.17 |
.37 |
1.19 |
|
Kras |  |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
Lat |  |
NM_010689 |
linker for activation of T cells (Lat), mRNA [NM_010689] |
KLA | .91 |
.95 |
.94 |
.87 |
.76 |
.63 |
.48 |
| ATP | .97 |
.99 |
1.01 |
1.50 |
1.59 |
1.49 |
1.00 |
| KLA/ATP | .91 |
1.04 |
.93 |
1.15 |
1.11 |
.96 |
.65 |
|
Lcp2 |  |
NM_010696 |
lymphocyte cytosolic protein 2 (Lcp2), mRNA [NM_010696] |
KLA | 9.10 |
9.37 |
9.29 |
7.53 |
9.33 |
5.54 |
4.23 |
| ATP | 1.25 |
1.38 |
.95 |
1.73 |
2.80 |
2.13 |
1.06 |
| KLA/ATP | 10.47 |
10.89 |
6.89 |
11.38 |
3.88 |
1.80 |
2.82 |
|
Lyn |  |
NM_010747 |
Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] |
KLA | 2.48 |
2.80 |
3.76 |
3.81 |
5.30 |
4.57 |
2.46 |
| ATP | 1.06 |
1.18 |
.82 |
.97 |
.74 |
1.45 |
1.21 |
| KLA/ATP | 2.82 |
3.16 |
2.24 |
2.87 |
1.73 |
1.80 |
2.63 |
|
Map2k1 |  |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k2 |  |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Map2k3 |  |
NM_008928 |
mitogen-activated protein kinase kinase 3 (Map2k3), mRNA [NM_008928] |
KLA | .88 |
.88 |
.73 |
.65 |
.99 |
1.34 |
.92 |
| ATP | 1.04 |
1.09 |
.89 |
1.62 |
1.93 |
1.75 |
1.17 |
| KLA/ATP | 1.00 |
.92 |
.66 |
1.21 |
1.80 |
2.24 |
2.10 |
|
Map2k4 |  |
NM_009157 |
mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] |
KLA | 3.67 |
3.75 |
4.23 |
3.90 |
3.30 |
1.87 |
1.12 |
| ATP | 1.05 |
1.11 |
1.04 |
.93 |
1.16 |
2.62 |
1.02 |
| KLA/ATP | 3.70 |
4.13 |
3.27 |
4.13 |
2.98 |
3.03 |
1.82 |
|
Map2k6 |  |
NM_011943 |
mitogen-activated protein kinase kinase 6 (Map2k6), mRNA [NM_011943] |
KLA | .68 |
.67 |
.64 |
.67 |
.62 |
.59 |
.61 |
| ATP | 1.02 |
1.12 |
1.04 |
1.10 |
.79 |
.61 |
.61 |
| KLA/ATP | .73 |
.69 |
.71 |
.74 |
.66 |
.62 |
.98 |
|
Map2k7 |  |
BC070467 |
mitogen activated protein kinase kinase 7, mRNA (cDNA clone MGC:96654 IMAGE:30615302), complete cds [BC070467] |
KLA | .77 |
.79 |
.88 |
.77 |
.97 |
.96 |
1.27 |
| ATP | 1.11 |
1.26 |
.93 |
1.19 |
1.13 |
1.45 |
1.16 |
| KLA/ATP | .89 |
.88 |
.59 |
.89 |
.86 |
1.32 |
1.28 |
|
Map2k7 |  |
NM_001042557 |
mitogen-activated protein kinase kinase 7 (Map2k7), transcript variant 1, mRNA [NM_001042557] |
KLA | .96 |
.95 |
1.02 |
.96 |
.95 |
1.09 |
1.19 |
| ATP | 1.02 |
1.07 |
.88 |
.97 |
.93 |
1.10 |
1.17 |
| KLA/ATP | 1.01 |
.99 |
.80 |
.87 |
.76 |
1.21 |
1.16 |
|
Mapk1 |  |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 |  |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk10 |  |
AK076990 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] |
KLA | 1.03 |
1.05 |
.98 |
1.04 |
.94 |
.95 |
1.02 |
| ATP | 1.00 |
.99 |
1.06 |
.97 |
1.01 |
.96 |
.99 |
| KLA/ATP | 1.07 |
1.01 |
.95 |
1.05 |
.82 |
.95 |
.87 |
|
Mapk10 |  |
NM_009158 |
mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] |
KLA | .95 |
1.00 |
.97 |
1.01 |
.99 |
1.01 |
.95 |
| ATP | 1.01 |
1.02 |
.98 |
1.01 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.05 |
.99 |
1.01 |
.98 |
.92 |
.97 |
.98 |
|
Mapk11 |  |
NM_011161 |
mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] |
KLA | 1.28 |
1.30 |
1.41 |
1.46 |
1.58 |
1.29 |
.98 |
| ATP | .96 |
.95 |
.89 |
.82 |
.79 |
1.09 |
.85 |
| KLA/ATP | 1.44 |
1.42 |
1.32 |
1.23 |
1.23 |
.74 |
.66 |
|
Mapk12 |  |
NM_013871 |
mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] |
KLA | .94 |
.86 |
.87 |
.81 |
.77 |
.68 |
.49 |
| ATP | .97 |
.83 |
.92 |
.90 |
.86 |
.90 |
.51 |
| KLA/ATP | .91 |
.89 |
.88 |
.85 |
1.12 |
1.14 |
.53 |
|
Mapk13 |  |
NM_011950 |
mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] |
KLA | 1.22 |
1.21 |
1.35 |
1.26 |
1.24 |
1.13 |
1.01 |
| ATP | 1.08 |
1.00 |
1.20 |
1.20 |
1.13 |
1.22 |
1.39 |
| KLA/ATP | 1.22 |
1.27 |
1.30 |
1.30 |
1.21 |
1.11 |
1.47 |
|
Mapk14 |  |
NM_011951 |
mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] |
KLA | .70 |
.70 |
.62 |
.54 |
.67 |
.88 |
1.11 |
| ATP | 1.03 |
.98 |
.87 |
.69 |
.48 |
.78 |
.66 |
| KLA/ATP | .74 |
.68 |
.52 |
.46 |
.38 |
.45 |
.62 |
|
Mapk3 |  |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mapk8 |  |
AK162915 |
adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] |
KLA | .94 |
.86 |
.80 |
.83 |
.77 |
.85 |
.83 |
| ATP | 1.08 |
1.12 |
.94 |
.80 |
.83 |
.71 |
.75 |
| KLA/ATP | .83 |
.81 |
.80 |
.74 |
.74 |
.75 |
.67 |
|
Mapk8 |  |
AK163829 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] |
KLA | .65 |
.61 |
.66 |
.70 |
.90 |
1.02 |
1.03 |
| ATP | .99 |
.94 |
1.68 |
1.44 |
1.75 |
1.84 |
1.10 |
| KLA/ATP | .63 |
.67 |
1.11 |
1.00 |
2.01 |
1.68 |
1.15 |
|
Mapk8 |  |
NM_016700 |
mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] |
KLA | .96 |
1.00 |
.94 |
.96 |
.94 |
.99 |
1.04 |
| ATP | 1.01 |
1.05 |
1.01 |
.99 |
1.03 |
.98 |
1.02 |
| KLA/ATP | .96 |
.97 |
.96 |
.97 |
.93 |
.94 |
.96 |
|
Mapk9 |  |
NM_016961 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] |
KLA | 1.28 |
1.37 |
1.59 |
1.60 |
1.61 |
1.43 |
1.38 |
| ATP | 1.03 |
.99 |
.74 |
.71 |
.79 |
1.20 |
1.01 |
| KLA/ATP | 1.53 |
1.30 |
1.07 |
.99 |
.83 |
1.10 |
1.40 |
|
Mapk9 |  |
NM_207692 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] |
KLA | 1.39 |
1.53 |
1.69 |
1.69 |
1.55 |
1.44 |
1.51 |
| ATP | .95 |
.92 |
.75 |
.85 |
.70 |
1.46 |
1.17 |
| KLA/ATP | 1.37 |
1.35 |
.99 |
1.18 |
.91 |
1.22 |
1.62 |
|
Mm.21312 8 |  |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.25381 9 |  |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.27970
|  |
13994135 |
Unknown |
KLA | 1.06 |
1.11 |
1.16 |
1.07 |
1.11 |
1.08 |
.95 |
| ATP | 1.02 |
1.09 |
1.05 |
1.05 |
.94 |
1.16 |
1.32 |
| KLA/ATP | 1.10 |
1.19 |
1.11 |
1.04 |
1.08 |
1.02 |
1.33 |
|
Mm.33050 7 |  |
67906182 |
Unknown |
KLA | .94 |
.98 |
.99 |
1.03 |
1.05 |
1.07 |
.98 |
| ATP | .95 |
1.02 |
.97 |
.98 |
.99 |
1.05 |
1.02 |
| KLA/ATP | 1.02 |
1.05 |
1.01 |
1.03 |
.99 |
.98 |
.97 |
|
Mm.41292 2 |  |
145966829 |
Unknown |
KLA | 3.65 |
3.76 |
3.75 |
3.79 |
3.42 |
1.75 |
1.10 |
| ATP | 1.11 |
1.17 |
1.04 |
.90 |
1.37 |
2.90 |
1.00 |
| KLA/ATP | 3.31 |
3.97 |
3.38 |
3.84 |
3.04 |
3.31 |
2.09 |
|
Mm.44463
|  |
118129851 |
Unknown |
KLA | 1.01 |
.98 |
.97 |
1.02 |
.93 |
1.06 |
1.05 |
| ATP | .97 |
1.01 |
1.04 |
1.06 |
1.02 |
1.08 |
.97 |
| KLA/ATP | 1.02 |
1.06 |
.95 |
1.04 |
1.09 |
1.14 |
1.03 |
|
Ms4a2 |  |
NM_013516 |
membrane-spanning 4-domains, subfamily A, member 2 (Ms4a2), mRNA [NM_013516] |
KLA | 1.02 |
.96 |
1.07 |
1.01 |
1.04 |
1.01 |
.97 |
| ATP | 1.03 |
.97 |
1.10 |
1.01 |
1.00 |
.96 |
.96 |
| KLA/ATP | .99 |
.98 |
.99 |
.99 |
1.03 |
.99 |
1.00 |
|
Nras |  |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Pdk1 |  |
AK165090 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330005M21 product:hypothetical protein, full insert sequence. [AK165090] |
KLA | .86 |
.77 |
.71 |
.67 |
.45 |
.29 |
.35 |
| ATP | 1.06 |
.88 |
1.21 |
.72 |
.60 |
.26 |
.15 |
| KLA/ATP | .81 |
.74 |
.97 |
.57 |
.51 |
.22 |
.09 |
|
Pdk1 |  |
NM_172665 |
pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA [NM_172665] |
KLA | .92 |
.94 |
.91 |
.79 |
.63 |
.46 |
.51 |
| ATP | .95 |
1.03 |
1.06 |
1.02 |
.63 |
.31 |
.37 |
| KLA/ATP | .88 |
.91 |
.91 |
.89 |
.62 |
.31 |
.27 |
|
Pik3ca |  |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca |  |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb |  |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd |  |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd |  |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg |  |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 |  |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 |  |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 |  |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 |  |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Pla2g4a |  |
NM_008869 |
phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] |
KLA | 3.93 |
4.49 |
4.86 |
6.40 |
6.44 |
3.10 |
1.68 |
| ATP | 1.13 |
1.36 |
1.27 |
1.30 |
1.02 |
5.37 |
1.47 |
| KLA/ATP | 3.64 |
4.45 |
4.76 |
7.11 |
2.96 |
4.08 |
2.60 |
|
Pla2g4b |  |
NM_145378 |
phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] |
KLA | 1.09 |
1.18 |
.95 |
1.01 |
.97 |
.97 |
.77 |
| ATP | 1.05 |
1.14 |
1.28 |
.94 |
.88 |
1.18 |
.70 |
| KLA/ATP | 1.23 |
1.43 |
1.21 |
1.02 |
1.15 |
1.16 |
.78 |
|
Pla2g4c |  |
AK145339 |
1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] |
KLA | 1.09 |
1.21 |
1.33 |
1.17 |
1.26 |
1.30 |
1.05 |
| ATP | .97 |
1.06 |
1.00 |
.98 |
.98 |
.98 |
1.05 |
| KLA/ATP | 1.19 |
1.16 |
1.18 |
1.13 |
1.04 |
1.02 |
1.06 |
|
Pla2g4c |  |
NM_001004762 |
phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] |
KLA | .93 |
1.00 |
.94 |
.93 |
.94 |
.94 |
.96 |
| ATP | .98 |
.96 |
1.13 |
.97 |
.99 |
.89 |
.96 |
| KLA/ATP | 1.01 |
1.01 |
1.07 |
1.01 |
.94 |
1.01 |
.92 |
|
Pla2g4e |  |
AK049063 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] |
KLA | 1.03 |
1.09 |
1.01 |
1.01 |
1.06 |
.94 |
1.05 |
| ATP | 1.03 |
1.00 |
1.06 |
1.01 |
.96 |
1.05 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.01 |
.98 |
1.03 |
.95 |
1.01 |
|
Pla2g4e |  |
NM_177845 |
phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] |
KLA | .97 |
.95 |
1.01 |
.97 |
1.02 |
1.03 |
1.05 |
| ATP | .98 |
.99 |
1.00 |
1.10 |
.98 |
1.00 |
1.02 |
| KLA/ATP | 1.05 |
.93 |
.96 |
1.03 |
1.08 |
1.05 |
.99 |
|
Pla2g4f |  |
NM_001024145 |
phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] |
KLA | 1.08 |
.99 |
1.04 |
1.02 |
1.04 |
.98 |
1.01 |
| ATP | .99 |
1.04 |
.99 |
1.03 |
1.12 |
1.01 |
1.25 |
| KLA/ATP | .97 |
1.04 |
1.10 |
1.06 |
1.04 |
1.03 |
1.03 |
|
Plcg2 |  |
NM_172285 |
phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] |
KLA | .76 |
.74 |
.68 |
.66 |
.71 |
.92 |
.95 |
| ATP | .96 |
.90 |
.95 |
.87 |
.81 |
.79 |
.91 |
| KLA/ATP | .76 |
.71 |
.69 |
.62 |
.72 |
.78 |
.68 |
|
Prkca |  |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
Prkcb1 |  |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
Prkcd |  |
NM_011103 |
protein kinase C, delta (Prkcd), mRNA [NM_011103] |
KLA | 1.72 |
1.84 |
1.90 |
1.68 |
2.01 |
1.61 |
1.64 |
| ATP | 1.00 |
1.03 |
.68 |
.81 |
1.38 |
1.26 |
.98 |
| KLA/ATP | 1.77 |
1.79 |
1.16 |
1.19 |
1.33 |
1.25 |
1.56 |
|
Prkce |  |
AK017901 |
adult male thymus cDNA, RIKEN full-length enriched library, clone:5830406C15 product:unclassifiable, full insert sequence. [AK017901] |
KLA | 1.63 |
1.44 |
1.95 |
2.09 |
1.96 |
1.34 |
1.56 |
| ATP | .99 |
.83 |
.85 |
.78 |
.85 |
2.44 |
1.47 |
| KLA/ATP | 1.36 |
1.45 |
1.44 |
1.23 |
1.30 |
2.39 |
2.29 |
|
Prkce |  |
AK042994 |
7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730046G04 product:protein kinase C, epsilon, full insert sequence. [AK042994] |
KLA | 1.01 |
1.07 |
1.03 |
1.03 |
1.04 |
1.00 |
1.06 |
| ATP | .99 |
1.09 |
1.08 |
1.05 |
1.02 |
1.06 |
1.07 |
| KLA/ATP | 1.00 |
.90 |
1.06 |
1.14 |
1.10 |
1.08 |
1.09 |
|
Rac1 |  |
NM_009007 |
RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] |
KLA | 1.02 |
1.01 |
1.02 |
.99 |
1.03 |
1.15 |
1.08 |
| ATP | .99 |
1.15 |
1.01 |
1.27 |
1.06 |
1.20 |
1.06 |
| KLA/ATP | 1.00 |
1.04 |
.88 |
1.16 |
.91 |
1.21 |
1.38 |
|
Rac2 |  |
NM_009008 |
RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] |
KLA | 1.55 |
1.68 |
1.86 |
2.15 |
3.36 |
3.59 |
3.74 |
| ATP | 1.13 |
1.16 |
.74 |
.99 |
.84 |
.91 |
1.66 |
| KLA/ATP | 1.59 |
1.71 |
1.19 |
1.56 |
1.21 |
1.60 |
3.48 |
|
Rac3 |  |
NM_133223 |
RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] |
KLA | 2.03 |
2.20 |
2.64 |
2.18 |
2.95 |
2.29 |
1.41 |
| ATP | 1.02 |
1.12 |
.94 |
1.42 |
1.16 |
.84 |
.87 |
| KLA/ATP | 2.30 |
2.32 |
1.57 |
2.55 |
1.75 |
1.47 |
1.61 |
|
Raf1 |  |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 |  |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Sos1 |  |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 |  |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Syk |  |
NM_011518 |
spleen tyrosine kinase (Syk), mRNA [NM_011518] |
KLA | 2.48 |
2.59 |
2.57 |
2.26 |
3.29 |
3.75 |
3.19 |
| ATP | .96 |
.85 |
.59 |
1.01 |
2.80 |
3.77 |
2.11 |
| KLA/ATP | 2.56 |
2.09 |
1.16 |
1.35 |
2.50 |
4.33 |
5.10 |
|
Tnf |  |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Vav1 |  |
NM_011691 |
vav 1 oncogene (Vav1), mRNA [NM_011691] |
KLA | .79 |
.83 |
.98 |
1.17 |
1.97 |
2.42 |
2.26 |
| ATP | 1.06 |
1.02 |
.88 |
1.01 |
1.34 |
.82 |
1.36 |
| KLA/ATP | .88 |
.85 |
.73 |
.78 |
1.25 |
1.47 |
2.17 |
|
Vav2 |  |
BC053060 |
vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] |
KLA | .73 |
.58 |
.55 |
1.16 |
.76 |
1.35 |
1.75 |
| ATP | .99 |
.89 |
.79 |
.82 |
.67 |
.85 |
1.09 |
| KLA/ATP | .64 |
.63 |
.61 |
.65 |
.66 |
.80 |
1.23 |
|
Vav2 |  |
NM_009500 |
vav 2 oncogene (Vav2), mRNA [NM_009500] |
KLA | .98 |
1.05 |
.98 |
.99 |
1.02 |
1.36 |
1.43 |
| ATP | 1.07 |
1.06 |
.96 |
1.01 |
.89 |
.95 |
1.08 |
| KLA/ATP | 1.04 |
1.05 |
.98 |
1.03 |
.88 |
.99 |
1.13 |
|
Vav3 |  |
NM_020505 |
vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] |
KLA | .95 |
.94 |
.86 |
.87 |
.82 |
.66 |
.56 |
| ATP | 1.06 |
1.09 |
.81 |
1.05 |
.80 |
.75 |
.85 |
| KLA/ATP | 1.00 |
.84 |
.62 |
.85 |
.74 |
.56 |
.74 |
|